Wendy Johnson

Wendy is the Chief Business Officer of Reneo Pharmaceuticals. Previously, Wendy served as Reneo's Chief Development Officer and was the company's founding Chief Operating Officer. Wendy brings more than 30 years of experience in drug development, venture capital, licensing, strategy, and corporate development. Prior to joining Reneo, Wendy was interim Chief Operating Officer and board member of AmpliPhi Bioscience (now Armata Pharmaceuticals). Wendy serves on the board of MorphoSys AG, a publicly held biotechnology company. Wendy previously served on the investment team at ProQuest Investments and was president and CEO of Aires Pharmaceuticals, acquired by Mast Therapeutics. She also served as senior vice president of corporate development at Salmedix until its acquisition by Cephalon/Teva and held executive roles at Women First Healthcare, Selective Genetics, and Cytel. Earlier in her career, she was assistant director of the Center for Devices and Radiological Health at the U.S. Food and Drug Administration. Wendy holds an M.B.A. from Loyola University, an M.S. in clinical microbiology from the Hahnemann Medical School, and a B.S. in microbiology from the University of Maryland.